Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 11
Submit an article Journal homepage
3,270
Views
20
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma

Ajai ChariIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA; Correspondence[email protected]
,
Sarah LarsonUniversity of California, Los Angeles, CA, USA;
,
Beata HolkovaVirginia Commonwealth University Medical Center, Richmond, VA, USA;
,
Robert F. CornellVanderbilt-Ingram Cancer Center, Nashville, TN, USA;
,
Cristina GasparettoDuke University Medical Center, Durham, NC, USA;
,
Chatchada KaranesCity of Hope National Medical Center, Duarte, CA, USA;
,
Jeffrey V. MatousColorado Blood Cancer Institute, Denver, CO, USA;
,
Ruben NiesvizkyWeill Cornell Medical College, New York, NY, USA;
,
Jason ValentCleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA;
,
Matthew LunningUniversity of Nebraska Medical Center, Omaha, NE, USA;
,
Saad Z. UsmaniLevine Cancer Institute/Carolinas Healthcare System, Charlotte, NC, USA;
,
Larry D. Anderson JrSimmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA;
,
Lipo ChangPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA;
,
Yihua LeePharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA;
,
Yvonne PakPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA;
,
Zeena SalmanPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA;
,
Thorsten GraefPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA;
,
Elizabeth BilottiPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA;
&
Saurabh ChhabraMedical University of South Carolina, Charleston, SC, USA
 show all
Pages 2588-2594 | Received 10 Jan 2018, Accepted 11 Feb 2018, Published online: 04 Apr 2018

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

K Groen, NWCJ van de Donk, CAM Stege, S Zweegman & IS Nijhof. (2019) Carfilzomib for relapsed and refractory multiple myeloma. Cancer Management and Research 11, pages 2663-2675.
Read now
Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Efstathios Kastritis, Evangelos Terpos & Meletios A Dimopoulos. (2019) Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. Expert Review of Anticancer Therapy 19:11, pages 921-928.
Read now
Judith Lind, Felix Czernilofsky, Sonia Vallet & Klaus Podar. (2019) Emerging protein kinase inhibitors for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs 24:3, pages 133-152.
Read now
Morie A. Gertz. (2018) Multiple myeloma – a cure within reach. Leukemia & Lymphoma 59:11, pages 2521-2523.
Read now

Articles from other publishers (16)

Krishnakumar Rathnam, S. V. Saju & Susan Raju Honey. (2022) Management of Relapsed and Refractory Multiple Myeloma: Recent advances. Indian Journal of Medical and Paediatric Oncology 43:06, pages 458-472.
Crossref
Aqu Alu, Hong Lei, Xuejiao Han, Yuquan Wei & Xiawei Wei. (2022) BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. Journal of Hematology & Oncology 15:1.
Crossref
Weam Othman Elbezanti, Omar S. Al-Odat, Robert Chitren, Jaikee Kumar Singh, Sandeep Kumar Srivastava, Krishne Gowda, Shantu Amin, Gavin P. Robertson, Venkatesh V. Nemmara, Subash C. Jonnalagadda, Tulin Budak-Alpdogan & Manoj K. Pandey. (2022) Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells. Frontiers in Pharmacology 13.
Crossref
Manuel Ramos-Casals, Alejandra Flores-Chávez, Pilar Brito-Zerón, Olivier Lambotte & Xavier Mariette. (2022) Immune-related adverse events of cancer immunotherapies targeting kinases. Pharmacology & Therapeutics 237, pages 108250.
Crossref
Igor Valentim Barreto, Caio Bezerra Machado, Davi Benevides Almeida, Flávia Melo Cunha de Pinho Pessoa, Renan Brito Gadelha, Laudreísa da Costa Pantoja, Deivide de Sousa Oliveira, Rodrigo Monteiro Ribeiro, Germison Silva Lopes, Manoel Odorico de Moraes Filho, Maria Elisabete Amaral de Moraes, André Salim Khayat, Edivaldo Herculano Correa de Oliveira & Caroline Aquino Moreira-Nunes. (2022) Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives. Pharmaceutics 14:9, pages 1784.
Crossref
Max Von Suskil, Kazi Nasrin Sultana, Weam Othman Elbezanti, Omar S. Al-Odat, Robert Chitren, Amit K. Tiwari, Kishore B. Challagundla, Sandeep Kumar Srivastava, Subash C. Jonnalagadda, Tulin Budak-Alpdogan & Manoj K. Pandey. (2021) Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma. International Journal of Molecular Sciences 22:11, pages 5707.
Crossref
Emilie Logie, Chandra S. Chirumamilla, Claudina Perez-Novo, Priyanka Shaw, Ken Declerck, Ajay Palagani, Savithri Rangarajan, Bart Cuypers, Nicolas De Neuter, Fazil Mobashar Hussain Urf Turabe, Navin Kumar Verma, Annemie Bogaerts, Kris Laukens, Fritz Offner, Pieter Van Vlierberghe, Xaveer Van Ostade & Wim Vanden Berghe. (2021) Covalent Cysteine Targeting of Bruton’s Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells. Cancers 13:7, pages 1618.
Crossref
Tina Paradzik, Cecilia Bandini, Elisabetta Mereu, Maria Labrador, Elisa Taiana, Nicola Amodio, Antonino Neri & Roberto Piva. (2021) The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma. Cancers 13:6, pages 1235.
Crossref
Azka Latif, Vikas Kapoor, Noman Lateef, Muhammad J. Ahsan, Rana M. Usman, Saad U. Malik, Naqib Ahmad, Nathaniel Rosko, Joslyn Rudoni, Preethi William, Jack Khouri & Faiz Anwer. (2021) Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis. Cardiovascular & Hematological Disorders-Drug Targets 21:1, pages 30-45.
Crossref
Tingyu Wen, Jinsong Wang, Yuankai Shi, Haili Qian & Peng Liu. (2020) Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances. Leukemia 35:2, pages 312-332.
Crossref
Ajai Chari, Robert F. Cornell, Cristina Gasparetto, Chatchada Karanes, Jeffrey V. Matous, Ruben Niesvizky, Matthew Lunning, Saad Z. Usmani, Larry D. AndersonJrJr, Saurabh Chhabra, Saulius Girnius, Chaim Shustik, Robert Stuart, Yihua Lee, Zeena Salman, Emily Liu & Jason Valent. (2020) Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematological Oncology 38:3, pages 353-362.
Crossref
Roman Hajek, Ludek Pour, Muhit Ozcan, Jesus Martin Sánchez, Ramon García Sanz, Achilles Anagnostopoulos, Albert Oriol, Nicola Cascavilla, Andreas Terjung, Yihua Lee, Eva M. Briso, Edyta Dobkowska, Bernhard Hauns & Ivan Špička. (2020) A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. European Journal of Haematology 104:5, pages 435-442.
Crossref
Hun J. Lee, Jacob L. Schmelz, Fred Cramer, Jorge E. Romaguera, Maria Badillo & Michael Wang. (2020) A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma. British Journal of Haematology 188:6.
Crossref
Ceren Durer, Seren Durer, Sarah Lee, Rajshekhar Chakraborty, Mustafa Nadeem Malik, Abdul Rafae, Muhammad Abu Zar, Ahmad Kamal, Nathaniel Rosko, Christy Samaras, Jason Valent, Chakra Chaulagain & Faiz Anwer. (2019) Treatment of relapsed multiple myeloma: Evidence-based recommendations. Blood Reviews, pages 100616.
Crossref
Vivek G. Patel & Robert F. Cornell. (2019) Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management. Current Oncology Reports 21:4.
Crossref
Christian Schmidl, Gregory I. Vladimer, André F. Rendeiro, Susanne Schnabl, Thomas Krausgruber, Christina Taubert, Nikolaus Krall, Tea Pemovska, Mohammad Araghi, Berend Snijder, Rainer Hubmann, Anna Ringler, Kathrin Runggatscher, Dita Demirtas, Oscar Lopez de la Fuente, Martin Hilgarth, Cathrin Skrabs, Edit Porpaczy, Michaela Gruber, Gregor Hoermann, Stefan Kubicek, Philipp B. Staber, Medhat Shehata, Giulio Superti-Furga, Ulrich Jäger & Christoph Bock. (2019) Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL. Nature Chemical Biology 15:3, pages 232-240.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.